Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy

By Yokota Toshifumi   Pistilli Emidio   Duddy William   Nagaraju Kanneboyina  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 6, 2007-06 ,pp. : 831-842

Informa Healthcare

Access to resources Recommend Favorite

Developing Effective Therapy for Duchenne Muscular Dystrophy (DMD): Challenges and Promises

By  

Current Chemical Biology, Vol. 8, Iss. 3, 2014-01 ,pp. : 117-131

Bentham Science Publishers

Access to resources Recommend Favorite

Increased Number of Caveolae and Caveolin-3 Overexpression in Duchenne Muscular Dystrophy

By Repetto S.   Bado M.   Broda P.   Lucania G.   Masetti E.   Sotgia F.   Carbone I.   Pavan A.   Bonilla E.   Cordone G.   Lisanti M.P.   Minetti C.  

Biochemical and Biophysical Research Communications, Vol. 261, Iss. 3, 1999-08 ,pp. : 547-550

Elsevier

Access to resources Recommend Favorite

The Concomitant Use of Dystrophin and Utrophin/Dystrophin Related Protein Antibodies to Reduce Misdiagnosis of Duchenne/Becker Muscular Dystrophy

By Khurana T.S.   Specht L.A.   Beggs A.H.   Tomé F.M.S.   Letureq F.   Chevallay M.   Chafey P.   Kunkel L.M.  

Biochemical and Biophysical Research Communications, Vol. 241, Iss. 2, 1997-12 ,pp. : 232-235

Elsevier

Access to resources Recommend Favorite

Decreased Expression of Brain &bgr;-Dystroglycan in Duchenne Muscular Dystrophy but Not in the mdx Animal Model

By Finn D.M.   Culligan K.G.   Ohlendieck K.  

Biochemical and Biophysical Research Communications, Vol. 249, Iss. 1, 1998-08 ,pp. : 231-235

Elsevier

Access to resources Recommend Favorite